TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reiterated by equities research analysts at Wedbush in a note issued to investors on Tuesday,RTT News reports. They currently have a $7.00 price target on the stock. Wedbush's target price would suggest a potential upside of 324.24% from the stock's previous close.
Several other brokerages have also recently issued reports on TCRX. HC Wainwright decreased their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TScan Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $7.80.
Check Out Our Latest Research Report on TCRX
TScan Therapeutics Price Performance
Shares of TCRX stock traded up $0.04 during trading hours on Tuesday, hitting $1.65. 132,344 shares of the company's stock were exchanged, compared to its average volume of 474,229. The firm has a 50 day moving average of $1.67 and a two-hundred day moving average of $1.68. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The firm has a market cap of $93.37 million, a P/E ratio of -1.51 and a beta of 0.99. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. The business had revenue of $2.17 million during the quarter, compared to analysts' expectations of $1.62 million. TScan Therapeutics had a negative return on equity of 55.76% and a negative net margin of 2,974.08%. Sell-side analysts forecast that TScan Therapeutics will post -1.12 EPS for the current year.
Insider Buying and Selling
In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $1,440,000.00. Following the transaction, the insider owned 7,946,141 shares of the company's stock, valued at $9,535,369.20. The trade was a 17.79% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.35% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new position in shares of TScan Therapeutics in the 4th quarter valued at approximately $40,000. Catalyst Funds Management Pty Ltd acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $26,000. Squarepoint Ops LLC acquired a new stake in TScan Therapeutics in the 4th quarter valued at approximately $59,000. Wells Fargo & Company MN grew its holdings in TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after buying an additional 5,694 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $29,000. 82.83% of the stock is owned by institutional investors.
About TScan Therapeutics
(
Get Free Report)
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.